

2008

# Vascular Endothelial Growth Factor (VEGF) Isoforms may Regulate Sex-Specific Vascular Development, Cord Formation and Follicle Progression in Developing Gonads

Andrea S. Cupp

*University of Nebraska at Lincoln*, [acupp2@unl.edu](mailto:acupp2@unl.edu)

Rebecca C. Bott

*South Dakota State University*, [Rebecca.Bott@sdstate.edu](mailto:Rebecca.Bott@sdstate.edu)

Renee M. Pohlmann

*University of Nebraska at Lincoln*, [rmcfee3@unl.edu](mailto:rmcfee3@unl.edu)

Robin A. Ten Broeck

*University of Nebraska at Lincoln*, [robs9227@yahoo.com](mailto:robs9227@yahoo.com)

Debra T. Clopton

*University of Nebraska at Lincoln*, [dclopton@unlnotes.unl.edu](mailto:dclopton@unlnotes.unl.edu)

Follow this and additional works at: <http://digitalcommons.unl.edu/animalscifacpub>



Part of the [Animal Sciences Commons](#)

---

Cupp, Andrea S.; Bott, Rebecca C.; Pohlmann, Renee M.; Ten Broeck, Robin A.; and Clopton, Debra T., "Vascular Endothelial Growth Factor (VEGF) Isoforms may Regulate Sex-Specific Vascular Development, Cord Formation and Follicle Progression in Developing Gonads" (2008). *Faculty Papers and Publications in Animal Science*. 595.

<http://digitalcommons.unl.edu/animalscifacpub/595>

This Article is brought to you for free and open access by the Animal Science Department at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Papers and Publications in Animal Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

1                   **VASCULAR ENDOTHELIAL GROWTH**  
2                   **FACTOR (VEGF) ISOFORMS MAY REGULATE**  
3                   **SEX-SPECIFIC VASCULAR DEVELOPMENT,**  
4                   **CORD FORMATION AND FOLLICLE**  
5                   **PROGRESSION IN DEVELOPING GONADS**

6                   AS Cupp, RC Bott, RM Pohlmann, RA Ten Broeck and DT Clopton  
7   Department of Animal Science  
8   University of Nebraska-Lincoln, Lincoln, NE, USA

9                   **Summary**

10                   The ratio of VEGF angiogenic to anti-angiogenic isoforms appears  
11                   to determine different biological functions in reproduction. Reduced  
12                   amounts of angiogenic VEGF isoforms inhibit testis sex-specific  
13                   vasculature and normal cord formation in organ cultures while reduction  
14                   of inhibitory isoforms increased vasculature and perturbed cords. In the  
15                   female, using peri-natal ovarian cultures, inhibition of angiogenic  
16                   VEGF isoforms reduced vascular development and inhibited follicle  
17                   progression while conversely reductions in inhibitory isoforms or  
18                   increases in angiogenic isoforms enhanced follicle development. Thus,  
19                   regulation of the *Vegfa* gene to produce angiogenic or anti-angiogenic  
20                   isoforms may be a mechanism to alter sex-specific vascular development,  
21                   formation of seminiferous cords, and/or follicle progression within  
22                   mammalian gonads.

23                   **Introduction**

24                   Infertility affects 40-70 million couples; of those approximately  
25                   50% of the infertility problems are attributed to male-related factors which  
26                   include: low sperm count, abnormal spermatogenesis, and reduced  
27                   androgen production [1, 2]. Formation of testicular cords, and sex-  
28                   specific vasculature, are the two morphological hallmarks that distinguish  
29                   a testis from an ovary. Female-related infertility factors include: ovulatory  
30                   disorders, anovulation due to polycystic ovarian disease and ovarian  
31                   hyperstimulation syndrome, or premature ovarian failure. Some or all of  
32                   these female infertility problems may be caused by improper prenatal  
33                   development of the fetal gonad, reduction of number of primordial  
34                   follicles or disruption of progression of folliculogenesis.  
35                   Neovascularization of the ovary and continued formation of follicle  
36                   vasculature are critical events in normal reproductive function.

37                   The VEGF family is composed of five ligands: VEGF (VEGF-A),  
38                   VEGF-B, VEGF-C, VEGF-D and Placenta Growth Factor. VEGF  
39                   (VEGF-A) is the best characterized and most potent VEGF molecule.  
40                   VEGF works through both Fms-like tyrosine kinase 1 (FLT1) and Kinase

41 domain region receptor (KDR), to elicit its effects on endothelial cell  
42 migration, differentiation, proliferation and survival and apoptosis. VEGF  
43 is transcribed from a single gene that has 8 exons and is alternatively  
44 spliced into different isoforms each containing a different number of  
45 amino acids. The most common angiogenic isoforms are VEGF205, 188,  
46 164, 144, and 120 [3].

47 In 2002, an additional isoform, VEGF164b, was identified which  
48 contained part of the 3' UTR that is now determined to be exon 8b.  
49 Furthermore, recent studies have demonstrated that the human VEGF165b  
50 isoform is anti-angiogenic in function and inhibits signal transduction  
51 through KDR [4, 5]. Thus, this isoform is inhibitory to the actions of  
52 VEGF. Therefore, it appears that for every angiogenic isoform there is a  
53 sister inhibitory isoform that is formed when exon 8a is replaced with  
54 exon 8b. These inhibitory (anti-angiogenic) isoforms serves to modulate  
55 the functions of the angiogenic VEGF isoforms.

## 56 **Materials and Methods**

57 *Rat Testis Organ cultures:* E13 testes with attached mesonephros  
58 were placed on Millicell CM filters (Millipore, Bedford MA) in drops of  
59 medium floating on the surface of 0.4 ml of CMRL 1066 media (Gibco  
60 BRL, Gaithersburg, MD) at conditions reported [6, 7]. One organ from  
61 each animal was designated as a vehicle control, while its pair was  
62 subjected to a VEGF receptor signal transduction inhibitor, VEGFR-TKI  
63 (8  $\mu$ M), or a VEGF antagonist, Je-11 (10  $\mu$ g/ml) [8]. *Whole-mount IHC*  
64 *and Confocal Microscopy:* After culture, the organs were fixed in 4%  
65 paraformaldehyde. Samples were washed, blocked and whole-mount IHC  
66 was conducted as reported [8]. *Vascular Density Quantification was*  
67 *conducted as reported* using the staining index in Scion Image [8].  
68 *Ovarian Organ Cultures:* Ovaries were dissected from postnatal day 3 and  
69 4 (P3/4) rats (day of birth was considered to be P0). One ovary from each  
70 animal was designated as a control, while its pair was subjected to  
71 Treatment with 8  $\mu$ M VEGFR-TKI; Calbiochem, La Jolla, CA or KDR  
72 signal transduction inhibitor, V1, (30  $\mu$ M; Calbiochem, La Jolla, CA),  
73 VEGFA164 (R & D Systems Inc., Minneapolis, MN) or VEGF165b  
74 antibody (5ng/ml or 50ng/ml) (Abcam, Cambridge, MA). All of these  
75 treatments were added daily to the culture medium of the treated wells.

## 76 **Results**

77 Treatment of testis organ cultures with tyrosine kinase inhibitors to  
78 the VEGF receptor signal transduction pathway (VEGFR-TKI) or to  
79 VEGF antagonists (Je11) disrupted both sex-specific vascular  
80 development and seminiferous cord formation. Vascular density was  
81 reduced by 90 and 46%, respectively (P < 0.01). Conversely, treatment

82 with VEGF angiogenic isoforms: VEGF164, VEGF120 or an antibody to  
83 the exon 8b which binds inhibitory isoforms increased vascular density  
84 50-100% over controls and resulted in swollen and perturbed testis cord  
85 formation. Thus angiogenic VEGF isoforms are important in establishing  
86 the sex-specific vascular development and too much inhibitory isoforms  
87 may alter the ability for this vasculature and subsequent testis cord  
88 formation to occur.

89 In the female, treatment of perinatal rat ovaries signal transduction  
90 inhibitors (VEGFR-TKI), antagonists to KDR (V1) arrested follicle  
91 development to later secondary follicle stages ( $P < 0.05$ ). In contrast,  
92 treatment with angiogenic VEGF isoforms or an antibody to inhibitory  
93 isoforms increased vascular development and accelerated follicle  
94 progression to later secondary follicle stages ( $P < 0.05$ ). Thus, we propose  
95 that amount of angiogenic to inhibitory VEGF isoforms modulates follicle  
96 progression and may determine whether an ovarian follicles continues to  
97 progress or undergoes atresia.

### 98 **Conclusion**

99 Approximately two million couples seek treatment for infertility  
100 every year and less than half find successful treatments [9, 10]. Infertility  
101 problems in at least half of these couples are a result of male-related  
102 factors that are created by testicular dysgenesis. Many of the problems  
103 associated with testicular dysgenesis are proposed to involve a disruption  
104 in embryonic differentiation of cells within the indifferent gonad resulting  
105 in altered testicular development. Elucidating the factors involved in sex-  
106 specific vascular development will allow for a better understanding of how  
107 transcription factors coordinate regulation of growth factors to result in a  
108 testis-specific vascular system. Furthermore, delineating the interaction of  
109 VEGF angiogenic and inhibitory isoforms in ovarian follicle arrest and or  
110 progression may also be an interesting piece in the puzzle of disorders  
111 that result in female infertility.

112

### 113 **References**

- 114 1. Skakkebaek, N.E., *Testicular dysgenesis syndrome: new*  
115 *epidemiological evidence*. Int J Androl, 2004. **27**(4): p. 189-91.
- 116 2. Skakkebaek, N.E., et al., *Association between testicular dysgenesis*  
117 *syndrome (TDS) and testicular neoplasia: evidence from 20 adult*  
118 *patients with signs of maldevelopment of the testis*. Apmis, 2003.  
119 **111**(1): p. 1-9; discussion 9-11.
- 120 3. Veikkola, T. and K. Alitalo, *VEGF's receptors and angiogenesis*.  
121 *Semin Cancer Biology*, 1999. **9**: p. 211-220.

- 122 4. Bates, D., et al., *VEGF<sub>165</sub>b, an Inhibitory Splice Variant of Vascular*  
123 *Endothelial Growth Factor, Is Down-Regulated in Renal Cell*  
124 *Carcinoma*. *Cancer Research*, 2002. **62**: p. 4123-4131.
- 125 5. Woolard, J., et al., *VEGF<sub>165</sub>b, an Inhibitory Vascular Endothelial*  
126 *Growth Factor Splice Variant: Mechanism of Action, In vivo Effect*  
127 *on Angiogenesis and Endogenous Protein Expression*. *Cancer*  
128 *Research*, 2004. **64**: p. 7822-7835.
- 129 6. Cupp, A., G. Kim, and M. Skinner, *Expression and Action of*  
130 *Transforming Growth Factor Beta (TGFβ1, TGFβ2, and TGFβ3)*  
131 *during Embryonic Rat Testis Development*. *Biology of*  
132 *Reproduction*, 1999. **60**: p. 1304-1313.
- 133 7. Cupp, A.S., et al., *Effect of transient embryonic in vivo exposure to*  
134 *the endocrine disruptor methoxychlor on embryonic and postnatal*  
135 *testis development*. *J Androl*, 2003. **24**(5): p. 736-45.
- 136 8. Bott, R.C., et al., *Vascular endothelial growth factor and kinase*  
137 *domain region receptor are involved in both seminiferous cord*  
138 *formation and vascular development during testis morphogenesis*  
139 *in the rat*. *Biol Reprod*, 2006. **75**(1): p. 56-67.
- 140 9. Carlsen, E., et al., *Longitudinal changes in semen parameters in*  
141 *young Danish men from the Copenhagen area*. *Hum Reprod*, 2005.  
142 **20**(4): p. 942-9.
- 143 10. Shaban, S., *Male Infertility Overview*.  
144 <http://www.ivf.com/shaban.html>, 2000.  
145  
146

147

148 Corresponding address: Andrea S Cupp, A224i Animal Science  
149 Department, 38<sup>th</sup> and Fair Street, University of Nebraska-Lincoln,  
150 Lincoln, NE 68583-0908. [acupp2@unl.edu](mailto:acupp2@unl.edu)  
151 Portions of this research were funded by grants to ASC from  
152 NIH/NICHD: HD41546-01; HD045350-01.